Skip to content
RDL Network logo
Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study — Rahul Aggarwal | RDL Network